FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1968785382> ?p ?o ?g. }

• W1968785382 endingPage "950" @default.
• W1968785382 startingPage "941" @default.
• W1968785382 abstract "The molecular basis of the clinical heterogeneity of prostate cancer (PCa) is not well understood.The purpose of our study was to identify and characterize genes in a clinically relevant gene expression signature in a subgroup of primary PCa positive for transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG).We studied gene expression profiles by unsupervised hierarchical clustering in 48 primary PCas from patients with a long clinical follow-up. Results were correlated with clinical outcome and validated in an independent patient cohort. Selected genes from a defined classifier were tested in vitro for biologic properties.Initial treatment of primary tumors was radical prostatectomy.Associations between clinical and histopathologic variables were evaluated by the Pearson χ(2) test, Mann-Whitney U test, or Kruskal-Wallis test, where appropriate. The log-rank test or Breslow method was used for statistical analysis of Kaplan-Meier survival curves.Most tumors that overexpressed ERG clustered separately from other primary PCas. No differences in any clinical end points between ERG-positive and ERG-negative cancers were detected. Importantly, within the ERG-positive samples, two subgroups were identified, which differed significantly in prostate-specific antigen recurrence-free survival, and cancer-specific and overall survival. From our findings, we defined a gene expression classifier of 36 genes. In a second, completely independent tumor set, the classifier also distinguished ERG-positive subgroups with different clinical outcome. In both patient cohorts, the classifier was not predictive in ERG-negative tumors. Biologic processes regulated by genes in the classifier included cell adhesion and bone remodeling. Tumor growth factor-β signaling was indicated as the main differing signaling pathway between the two ERG subgroups. In vitro biologic assays of two selected genes from the classifier (inhibin, beta A [INHBA] and cadherin 11, type 2, OB-cadherin (osteoblast) [CDH11]) supported a functional role in PCa progression. Possible multifocality and limited number of PCa samples can be limitations of the study.The classifier identified can contribute to prediction of tumor progression in ERG-positive primary prostate tumors and might be instrumental in therapy decisions." @default.
• W1968785382 created "2016-06-24" @default.
• W1968785382 creator A5026981971 @default.
• W1968785382 creator A5034635531 @default.
• W1968785382 creator A5080250383 @default.
• W1968785382 creator A5081840836 @default.
• W1968785382 creator A5086560906 @default.
• W1968785382 date "2013-12-01" @default.
• W1968785382 modified "2023-10-14" @default.
• W1968785382 title "A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers" @default.
• W1968785382 cites W1963749564 @default.
• W1968785382 cites W1964252337 @default.
• W1968785382 cites W1976677295 @default.
• W1968785382 cites W1994847090 @default.
• W1968785382 cites W1996386813 @default.
• W1968785382 cites W1998566859 @default.
• W1968785382 cites W2000056288 @default.
• W1968785382 cites W2005472560 @default.
• W1968785382 cites W2016371780 @default.
• W1968785382 cites W2018560195 @default.
• W1968785382 cites W2038611248 @default.
• W1968785382 cites W2049205984 @default.
• W1968785382 cites W2051025382 @default.
• W1968785382 cites W2058403800 @default.
• W1968785382 cites W2061891797 @default.
• W1968785382 cites W2070924431 @default.
• W1968785382 cites W2082462837 @default.
• W1968785382 cites W2087207490 @default.
• W1968785382 cites W2091481108 @default.
• W1968785382 cites W2094818686 @default.
• W1968785382 cites W2103526670 @default.
• W1968785382 cites W2107633226 @default.
• W1968785382 cites W2113962581 @default.
• W1968785382 cites W2121158863 @default.
• W1968785382 cites W2122861585 @default.
• W1968785382 cites W2146873467 @default.
• W1968785382 cites W2153762942 @default.
• W1968785382 cites W2165948908 @default.
• W1968785382 doi "https://doi.org/10.1016/j.eururo.2013.02.039" @default.
• W1968785382 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23490727" @default.
• W1968785382 hasPublicationYear "2013" @default.
• W1968785382 type Work @default.
• W1968785382 sameAs 1968785382 @default.
• W1968785382 citedByCount "30" @default.
• W1968785382 countsByYear W19687853822013 @default.
• W1968785382 countsByYear W19687853822014 @default.
• W1968785382 countsByYear W19687853822015 @default.
• W1968785382 countsByYear W19687853822016 @default.
• W1968785382 countsByYear W19687853822017 @default.
• W1968785382 countsByYear W19687853822018 @default.
• W1968785382 countsByYear W19687853822019 @default.
• W1968785382 countsByYear W19687853822020 @default.
• W1968785382 countsByYear W19687853822021 @default.
• W1968785382 countsByYear W19687853822023 @default.
• W1968785382 crossrefType "journal-article" @default.
• W1968785382 hasAuthorship W1968785382A5026981971 @default.
• W1968785382 hasAuthorship W1968785382A5034635531 @default.
• W1968785382 hasAuthorship W1968785382A5080250383 @default.
• W1968785382 hasAuthorship W1968785382A5081840836 @default.
• W1968785382 hasAuthorship W1968785382A5086560906 @default.
• W1968785382 hasConcept C103796816 @default.
• W1968785382 hasConcept C104317684 @default.
• W1968785382 hasConcept C118487528 @default.
• W1968785382 hasConcept C121608353 @default.
• W1968785382 hasConcept C126322002 @default.
• W1968785382 hasConcept C142724271 @default.
• W1968785382 hasConcept C143998085 @default.
• W1968785382 hasConcept C150194340 @default.
• W1968785382 hasConcept C2778042024 @default.
• W1968785382 hasConcept C2779134260 @default.
• W1968785382 hasConcept C2779466945 @default.
• W1968785382 hasConcept C2779733811 @default.
• W1968785382 hasConcept C2780192828 @default.
• W1968785382 hasConcept C2780827179 @default.
• W1968785382 hasConcept C3008058167 @default.
• W1968785382 hasConcept C524204448 @default.
• W1968785382 hasConcept C54355233 @default.
• W1968785382 hasConcept C71924100 @default.
• W1968785382 hasConcept C86803240 @default.
• W1968785382 hasConceptScore W1968785382C103796816 @default.
• W1968785382 hasConceptScore W1968785382C104317684 @default.
• W1968785382 hasConceptScore W1968785382C118487528 @default.
• W1968785382 hasConceptScore W1968785382C121608353 @default.
• W1968785382 hasConceptScore W1968785382C126322002 @default.
• W1968785382 hasConceptScore W1968785382C142724271 @default.
• W1968785382 hasConceptScore W1968785382C143998085 @default.
• W1968785382 hasConceptScore W1968785382C150194340 @default.
• W1968785382 hasConceptScore W1968785382C2778042024 @default.
• W1968785382 hasConceptScore W1968785382C2779134260 @default.
• W1968785382 hasConceptScore W1968785382C2779466945 @default.
• W1968785382 hasConceptScore W1968785382C2779733811 @default.
• W1968785382 hasConceptScore W1968785382C2780192828 @default.
• W1968785382 hasConceptScore W1968785382C2780827179 @default.
• W1968785382 hasConceptScore W1968785382C3008058167 @default.
• W1968785382 hasConceptScore W1968785382C524204448 @default.
• W1968785382 hasConceptScore W1968785382C54355233 @default.
• W1968785382 hasConceptScore W1968785382C71924100 @default.
• W1968785382 hasConceptScore W1968785382C86803240 @default.

• next